BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32100077)

  • 1. Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival.
    Karstens KF; Kempski J; Giannou AD; Pelczar P; Steglich B; Steurer S; Freiwald E; Woestemeier A; Konczalla L; Tachezy M; Reeh M; Bockhorn M; Perez D; Mann O; Lohse AW; Roesch T; Izbicki JR; Gagliani N; Huber S
    Cancer Immunol Immunother; 2020 Jun; 69(6):1043-1056. PubMed ID: 32100077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas.
    Karstens KF; Kempski J; Giannou AD; Freiwald E; Reeh M; Tachezy M; Izbicki JR; Lohse AW; Gagliani N; Huber S; Pelczar P
    PLoS One; 2020; 15(4):e0231833. PubMed ID: 32298379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid-induced TNFR family-related receptor (GITR)-expression in tumor infiltrating leucocytes (TILs) is associated with the pathogenesis of esophageal adenocarcinomas with and without Barrett's mucosa.
    von Rahden BH; Kircher S; Kafka M; Stuermer L; Reiber C; Gattenlöhner S; Germer CT; Grimm M
    Cancer Biomark; 2010; 7(6):285-94. PubMed ID: 21694467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.
    Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R
    Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
    Plum PS; Ulase D; Bollschweiler E; Chon SH; Berlth F; Zander T; Alakus H; Hölscher AH; Bruns CJ; Schallenberg S; Quaas A; Loeser H
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1731-1739. PubMed ID: 29974234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms of Genes Related to Function and Metabolism of Vitamin D in Esophageal Adenocarcinoma.
    Singhal S; Kapoor H; Subramanian S; Agrawal DK; Mittal SK
    J Gastrointest Cancer; 2019 Dec; 50(4):867-878. PubMed ID: 30187205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
    Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
    Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas.
    Ferrer-Torres D; Nancarrow DJ; Kuick R; Thomas DG; Nadal E; Lin J; Chang AC; Reddy RM; Orringer MB; Taylor JM; Wang TD; Beer DG
    Oncotarget; 2016 Aug; 7(34):54867-54882. PubMed ID: 27363029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
    Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
    Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early esophageal cancer in Europe: endoscopic treatment by endoscopic submucosal dissection.
    Probst A; Aust D; Märkl B; Anthuber M; Messmann H
    Endoscopy; 2015 Feb; 47(2):113-21. PubMed ID: 25479563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
    Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
    J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NcoI TNF-β gene polymorphism and TNF expression are associated with an increased risk of developing Barrett's esophagus and esophageal adenocarcinoma.
    Menke V; van Zoest KP; Moons LM; Hansen B; Pot RG; Siersema PD; Kusters JG; Kuipers EJ
    Scand J Gastroenterol; 2012 Apr; 47(4):378-86. PubMed ID: 22243485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux.
    Agarwal B; Swisher SG; Ajani J; Kelly K; Komaki RR; Abu-Hamda E; Correa AM; Roth JA
    Ann Thorac Surg; 2005 May; 79(5):1716-23. PubMed ID: 15854962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
    Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
    Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
    J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.